Symbols

BBIO

BridgeBio Pharma·NASDAQ

--(--)

BBIO fundamentals

BBIO Q4 2025 Earnings

BridgeBio Pharma (BBIO) released its earnings on Feb 24, 2026: revenue was 154.18M (YoY +2521.18%), beat estimates; EPS was -1 (YoY +28.57%), missed estimates.

Revenue / YoY

154.18M

+2521.18%

EPS / YoY

-1

+28.57%

Report date

Feb 24, 2026

BBIO Earnings Call Summary for Q4,2025

Revenue Growth: Q4 2025 Attruby net product revenue $146M, full-year 2025 total revenue $502M (+126% YoY).
Pipeline Milestones: 3 Phase III readouts (achondroplasia, LGMD2I, ADH1) with best-in-class data.
Cash Flow Outlook: 2028 EBITDA >$600M from 4 assets; 2026 cash burn stabilization, 2027 decline.
Attruby Differentiation: 2.1 cm/year growth in achondroplasia, 1-month clinical benefit onset, 50% price discount to competitors.
Infigratinib Market Share: 65% peak share vs. 52% prior estimate.

Earnings

EPS

Revenue

Revenue & Expenses

BBIO has released its 2025 Q4 earnings report, with revenue of 154.18M, reflecting a YoY change of 2521.18%, and net profit of -194.63M, showing a YoY change of 27.21%. The Sankey diagram below clearly presents BBIO's revenue sources and cost distribution.

Key Indicators

BridgeBio Pharma (BBIO) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

BridgeBio Pharma (BBIO)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

BridgeBio Pharma (BBIO)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

BridgeBio Pharma (BBIO)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown